Efficacy of Guselkumab on Axial-Related Symptoms Through up to 2 Years in Adults with Active Psoriatic Arthritis in the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Study

Abstract Introduction Guselkumab previously showed greater improvements versus placebo in axial symptoms in patients with psoriatic arthritis (PsA) (assessed by Bath Ankylosing Spondylitis Disease Activity Index [BASDAI] and Ankylosing Spondylitis Disease Activity Score [ASDAS]), in post hoc analyse...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Philip J. Mease, Dafna D. Gladman, Denis Poddubnyy, Soumya D. Chakravarty, May Shawi, Alexa P. Kollmeier, Xie L. Xu, Stephen Xu, Atul Deodhar, Xenofon Baraliakos
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Adis, Springer Healthcare 2023-10-01
coleção:	Rheumatology and Therapy
Assuntos:	Psoriatic arthritis Axial Biologics Guselkumab
Acesso em linha:	https://doi.org/10.1007/s40744-023-00592-8
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!